## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.98 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Analyst consensus $1199 (+15% upside). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($990.04)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 4, Bearish: 2)

**1. Indiana sues Eli Lilly alleging insulin price-fixing scheme**
- Source: WFYI | 20260105T200831 | Bearish | Relevance: 100%
- Indiana has filed a lawsuit against Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical company of inflating insulin prices through a secret rebate scheme with pharmacy benefit managers. The state alleges Lilly conspired to artificially raise sticker prices for insulin, driving up costs for patients despite low manufacturing costs. Eli Lilly asserts it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket expenses and cutting list prices.

**2. Indiana sues Eli Lilly over insulin prices**
- Source: WTHR | 20260105T110100 | Somewhat-Bearish | Relevance: 100%
- The state of Indiana is suing pharmaceutical giant Eli Lilly and Company, accusing it of colluding with other insulin makers to inflate insulin prices by over 1,000% in the last decade. Attorney General Todd Rokita is seeking market changes, damages, and penalties. Eli Lilly denies the allegations, stating it has made insulin more affordable and committed significant investment in the U.S.

**3. Sterling Investment Counsel LLC Buys 1,793 Shares of Eli Lilly and Company $LLY**
- Source: MarketBeat | 20260103T120758 | Bullish | Relevance: 100%
- Sterling Investment Counsel LLC significantly increased its holdings in Eli Lilly and Company by 427.9% in Q3, purchasing an additional 1,793 shares to bring its total to 2,212 shares valued at $1,688,000. This move aligns with a positive market sentiment, as Eli Lilly recently surpassed quarterly EPS and revenue expectations, raised its FY2025 EPS guidance, and increased its quarterly dividend. Institutional investors collectively own 82.53% of the company's stock, and analysts maintain a consensus "Buy" rating with an average target price of $1,155.36.

**4. Indiana AG files state lawsuit against Eli Lilly over insulin prices**
- Source: Fox 59 | 20260105T140823 | Bearish | Relevance: 99%
- Indiana Attorney General Todd Rokita has filed a lawsuit against Eli Lilly and Company, alleging the drugmaker conspired to raise insulin prices. This lawsuit follows an earlier one against other manufacturers and pharmacy benefit managers, where Lilly was initially named as a co-conspirator but not a defendant. Rokita claims Lilly's pricing scheme caused insulin prices to rise over 1000% in the last decade, violating Indiana state acts.

**5. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026**
- Source: Finviz | 20260105T135425 | Bullish | Relevance: 97%
- This article highlights five AI-powered medical stocks that are projected to build a strong portfolio in 2026. The medical sector has significantly adopted AI for diagnostics, drug synthesis, and operational efficiency, transforming some defensive low-beta stocks into high-growth providers. The featured companies are Eli Lilly and Co. (LLY), Medtronic plc (MDT), Intuitive Surgical Inc. (ISRG), Regeneron Pharmaceuticals Inc. (REGN), and Johnson & Johnson (JNJ), each leveraging AI to enhance their product offerings, operational efficiency, and market position.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 25 ($217.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $218M sold (25 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 31.9x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Insider selling cluster ($217.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $933.7B |
| Beta | 0.35 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 31.9 |
| Current P/E | 44.0 |
| YoY Growth | 37.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.1% to -0.8% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-4.08), momentum weakening. RSI neutral at 49. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.80% (CS: 32) | Neutral |
| RSI_14 | 49.4 | Neutral |
| MACD Histogram | -4.08 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.256x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1041.44
- **Stop Loss:** $990.04 (4.9% risk)
- **Target:** $1144.24 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $16,663.04
- **Portfolio %:** 16.66%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*